FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology

Sheikh, Ayesha; Rafique, Warisha; Owais, Rabia; Malik, Farheen; Ali, Eman

doi:10.1016/j.amsu.2022.104499

Cited by 28 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical Trials of topical JAK inhibitor Ruxolitinib cream met the primary endpoint in both pivotal phases 3 clinical trials with critical secondary endpoints, with a significantly higher proportion of the trial group achieving at least 75% improvement in the F-VASI score (a quantitative measure to assess skin symptoms in patients with vitiligo) relative to baseline than the placebo group at week 24 of treatment ( 118 ). Ruxolitinib cream is currently the first Food and Drug Administration (FDA) approved vitiligo therapy for the topical treatment of non-segmental vitiligo in adults and pediatric patients over 12 years of age ( 119 ). In addition, Shiu et al.…”

Section: New Therapeutic Strategies In Vitiligo Immunometabolismmentioning

confidence: 99%

Immunometabolism in the pathogenesis of vitiligo

Lyu

Sun

2022

Front. Immunol.

View full text Add to dashboard Cite

Vitiligo is a common depigmenting skin disorder characterized by the selective loss of melanocytes. Autoimmunity, genetic, environmental, and biochemical etiology have been proposed in vitiligo pathogenesis. However, the exact molecular mechanisms of vitiligo development and progression are unclear, particularly for immunometabolism. Sporadic studies have suggested mitochondrial dysfunction, enhanced oxidative stress, and specific defects in other metabolic pathways can promote dysregulation of innate and adaptive immune responses in vitiligo. These abnormalities appear to be driven by genetic and epigenetic factors modulated by stochastic events. In addition, glucose and lipid abnormalities in metabolism have been associated with vitiligo. Specific skin cell populations are also involved in the critical role of dysregulation of metabolic pathways, including melanocytes, keratinocytes, and tissue-resident memory T cells in vitiligo pathogenesis. Novel therapeutic treatments are also raised based on the abnormalities of immunometabolism. This review summarizes the current knowledge on immunometabolism reprogramming in the pathogenesis of vitiligo and novel treatment options.

show abstract

Section: New Therapeutic Strategies In Vitiligo Immunometabolismmentioning

confidence: 99%

Immunometabolism in the pathogenesis of vitiligo

Lyu

Sun

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…60 Recently, topical ruxolitinib cream has become the first and only FDA approved agent for repigmentation in patients with vitiligo. 61…”

Section: Ruxolitinibmentioning

confidence: 99%

An updated review on systemic and targeted therapies for vitiligo

Maghfour

Hamzavi

Mohammad

2022

Dermatological Reviews

View full text Add to dashboard Cite

Background: Vitiligo is a multifactorial disease characterized by depigmented macules and patches and is associated with a substantial disease burden. Systemic treatment of vitiligo is utilized for unstable or widespread disease. Materials and Methods:In this review, we will examine the evidence regarding the systemic agents that are currently used in the management of vitiligo, discuss emerging targeted therapies, and evaluate potential future treatment perspectives. Results: Although an array of systemic agents have been shown to halt disease progression in patients with vitiligo, their use is limited due to concerns regarding side effects and unclear efficacy. Targeted therapies such as topical ruxolitinib, a janus kinase inhibitor, has become the first and only FDA approved agent for repigmentation in patients with vitiligo. Discussion: In recent years, significant progress has been made in understanding the molecular and genetic factors influencing disease pathogenesis, enabling the development of targeted therapies, such as janus kinase inhibitors. Additional ongoing clinical trials are likely to improve the disease outcomes and quality of life of patients with vitiligo.

show abstract

“…Several new molecules have been recently developed to block this signaling pathway. The FDA has approved ruxolitinib (RUX), a Janus kinase (JAK)/STAT-3 inhibitor, for the treatment of primary myelofibrosis, polycythemia vera [ 14 ], and vitiligo [ 15 ], providing clinical validation of its effectiveness in inhibiting STAT-3.…”

Section: Introductionmentioning

confidence: 99%

Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells

et al. 2023

View full text Add to dashboard Cite

(1) Background: The current limitations of glioblastoma (GBM) chemotherapy were addressed by developing a molecularly imprinted polymer (MIP)-based drug reservoir designed for the localized and sustained release of ruxolitinib (RUX) within the tumor post-resection cavity, targeting residual infiltrative cancerous cells, with minimum toxic effects toward normal tissue. (2) Methods: MIP reservoirs were synthesized by precipitation polymerization using acrylamide, trifluoromethacrylic acid, methacrylic acid, and styrene as monomers. Drug release profiles were evaluated by real-time and accelerated release studies in phosphate-buffered solution as a release medium. The cytotoxicity of polymers and free monomers was evaluated in vitro on GBM C6 cells using the Alamar Blue assay, optical microscopy, and CCK8 cell viability assay. (3) Results: Among the four synthesized MIPs, trifluoromethacrylic acid-based polymer (MIP 2) was superior in terms of loading capacity (69.9 μg RUX/mg MIP), drug release, and efficacy on GBM cells. Accelerated drug release studies showed that, after 96 h, MIP 2 released 42% of the loaded drug at pH = 7.4, with its kinetics fitted to the Korsmeyer–Peppas model. The cell viability assay proved that all studied imprinted polymers provided high efficacy on GBM cells. (4) Conclusions: Four different drug-loaded MIPs were developed and characterized within this study, with the purpose of obtaining a drug delivery system (DDS) embedded in a fibrin-based hydrogel for the local, post-surgical administration of RUX in GBM in animal models. MIP 2 emerged as superior to the others, making it more suitable and promising for further in vivo testing.

show abstract

FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology

Cited by 28 publications

References 15 publications

Immunometabolism in the pathogenesis of vitiligo

Immunometabolism in the pathogenesis of vitiligo

An updated review on systemic and targeted therapies for vitiligo

Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells

Contact Info

Product

Resources

About